DARZALEX® Clinical Studies:

DARZALEX® as monotherapy

DARZALEX® was studied as monotherapy (by itself) in 106 people who had either received at least 3 prior medicines to treat their multiple myeloma, including a proteasome inhibitor (PI) and an immunomodulatory agent, or did not respond to a PI and an immunomodulatory agent. These people had received a median of five prior lines of therapy for their multiple myeloma.

The main goal of the study was to measure overall response rate, which is the percentage of people who responded to treatment.

Clinical trial results: DARZALEX® as monotherapy

When these people were treated with DARZALEX®, 29% responded. This response lasted for a median duration of 7.4 months (1.2 to 13.1+ months).

Of people who responded, response was seen between 0.9 and 5.6 months

1 month
Median time it took people to respond to DARZALEX®

5.6 months
Maximum time it took people to respond to DARZALEX®